SHR-9839
- Generic Name
- SHR-9839
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1
Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06754930
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 876
- Registration Number
- NCT06703177
- Locations
- 🇨🇳
Sun Yat-Sen university cancer center, Guangzhou, Guangdong, China
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Phase 1
- Conditions
- Advanced KRAS G12D Mutant Solid Tumors
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06385678
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT05836948
- Locations
- 🇨🇳
Zhejiang Tumor Hospital, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath